Abstract

ARMAS-CONDE, María De et al. Post-vaccination SARS-CoV-2 axillary adenopathy. Differences with axillary metastases from breast cancer. Cir. cir. [online]. 2022, vol.90, n.3, pp.410-413.  Epub June 06, 2022. ISSN 2444-054X.  https://doi.org/10.24875/ciru.21000737.

The differential diagnosis of the metastatic axillary lymphadenopathies of breast cancer with which they occur secondary to the Pfizer-BioNTech vaccine against COVID-19, is imperative. In a series of cases, we analyzed the characteristics of unilateral axillary lymphadenopathy in patients after Pfizer-BioNTech vaccination. Axillary lymphadenopathy were observed ipsilateral to the vaccination arm. The axillary ultrasound defined these as reactive and that they disappeared in 3 weeks. The pathological findings were benign. The anamnesis, the place and date of vaccination and the radiological findings, play an essential role to carry out a correct differential diagnosis and follow-up of these adenopathies.

Keywords : Axillary lymphadenopathy; Reactive adenopathies; COVID-19; Pfizer-BioNTech; Breast cancer; Vaccine.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )